Boeing's aerospace duopoly, record backlog, and profitable services franchise support a potential operational turnaround, but persistent production constraints, high leverage, and weak recurring cash generation leave the recovery vulnerable to further delays.
Sell-rated reports
287 tickers rated SellCheesecake Factory's powerful flagship brand and improving restaurant margins support earnings growth, but elevated valuation multiples and uncertainty around the durability of exceptional comparable sales limit investment appeal.
NIKE's global brand and historically low valuation create turnaround upside, but high-single-digit FY2027 revenue decline, China weakness and falling cash flow make the recovery too uncertain today.
RH has a differentiated luxury-design brand with real upside if RH Estates and global expansion restore earnings growth, but heavy leverage, housing-cycle exposure and unproven returns on its global push keep risk-reward unattractive.
Bullish could become an integrated leader in institutional digital asset and tokenized securities infrastructure, but substantial acquisition dilution, financing obligations, and uncertain recurring earnings constrain shareholder returns.
QXO offers substantial consolidation-driven growth and procurement synergies in North American building-products distribution, but heavy acquisition financing, dilution and weak cash conversion threaten common-shareholder returns.
Ionis has a differentiated RNA therapeutics platform, expanding approved-drug portfolio and valuable pipeline, but weak TRYNGOLZA adoption, substantial cash burn and uncertain profitability undermine its near-term investment appeal.
IDEAYA Biosciences could create substantial value through darovasertib approval and a differentiated precision-oncology pipeline, but persistent cash burn, dilution, and uncertain commercialization economics weaken the current investment case.
TeraWulf offers substantial long-term growth potential through contracted AI data center infrastructure, but heavy construction spending, external financing dependence, dilution, and demanding valuation undermine its near-term investment appeal.
10x Genomics could benefit from the structural expansion of spatial and single-cell biology, but weak consolidated growth, recurring operating losses, dilution, and an expensive valuation limit its investment appeal.
Materion benefits from specialized semiconductor and aerospace materials demand, record backlog, and improving cash generation, but demanding valuation and cyclical operating risks weaken the investment case.
BioNTech's substantial cash reserves and advanced oncology pipeline offer meaningful long-term upside, but declining vaccine revenue, persistent losses, and uncertain clinical commercialization limit near-term investment appeal.